Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
89bio ( (ETNB) ) has provided an announcement.
On December 12, 2024, 89bio, Inc. granted restricted stock units to key employees, including the Chief Medical Officer, Chief Technical Operations Officer, and Chief Financial Officer, as part of a retention strategy. This move is aimed at ensuring their continued service with the company, with the RSUs vesting semiannually over two years, potentially strengthening the company’s operational stability and retaining top talent.
More about 89bio
89bio, Inc. is a biopharmaceutical company focused on developing treatments for liver and cardio-metabolic diseases.
YTD Price Performance: -31.15%
Average Trading Volume: 790,338
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $904.2M
For detailed information about ETNB stock, go to TipRanks’ Stock Analysis page.
